| Last: 0.35 | Day Low: 0.35 | Volume: 60000 |  |
| Change: 0.00 | Day High: 0.35 | Date: 9/3/2010 |
Welcome to iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia. To date, iCo has reported positive preclinical results for iCo-009.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO".
